The Use of Allogenic Plasma Aliquots as a Source of Plasminogen in the Treatment of Ligneous Conjunctivitis, Clinical Trial of One Case
Who is this study for? Patients with Ligneous Conjunctivitis
What treatments are being studied? Allogenic Plasma Aliquots, a Source of Plasminogen
Status: Enrolling_by_invitation
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Allogenic plasma aliquots, used as eye drops, will provide a source of plasminogen in the treatment of ligneous conjunctivitis. The investigational product will be available through written request from the Sponsor-Investigator to Canadian Blood Services, as approved by Health Canada.
Eligibility
Participation Requirements
Sex: Female
Healthy Volunteers: t
View:
• Subject diagnosed with ligneous conjunctivitis associated with Type 1 plasminogen deficiency
Locations
Other Locations
Canada
Memorial University of Newfoundland
St. John's
Time Frame
Start Date: 2025-05
Completion Date: 2025-10
Participants
Target number of participants: 1
Treatments
Experimental: Allogenic Plasma Aliquots
Allogenic Plasma Aliquots to be used as eye drops in the treatment of recurrences of ligneous conjunctivitis. Two drops will be administered to the affected eye, every 1 to 4 hours, depending on severity of the recurrence.
Related Therapeutic Areas
Sponsors
Leads: Dorothy Bautista, MD
Collaborators: Canadian Blood Services